Pharmacological action not specified

The antibacterial property is similar to that of erythromycin. It has a strong antibacterial effect on Gram-positive bacteria, and is effective against Staphylococcus, Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae, Diphtheria bacillus, Tetanus bacillus, and anthrax bacillus. It also has antibacterial effects on Gram-negative bacteria such as gonococci and pertussis bacillus. It is also effective against Leptospira, Rickettsia, and Mycoplasma. It can be used as a substitute for erythromycin for infections of the oropharynx, respiratory tract, skin and soft tissue, and bile duct caused by the above-mentioned sensitive bacteria.

The antibacterial property is similar to that of erythromycin. It has a strong antibacterial effect on Gram-positive bacteria, and is effective against Staphylococcus, Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae, Diphtheria bacillus, Tetanus bacillus, and anthrax bacillus. It also has antibacterial effects on Gram-negative bacteria such as gonococci and pertussis bacillus. It is also effective against Leptospira, Rickettsia, and Mycoplasma. It can be used as a substitute for erythromycin for infections of the oropharynx, respiratory tract, skin and soft tissue, and bile duct caused by the above-mentioned sensitive bacteria.

Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent. Many Rickettsia, Mycoplasma, Chlamydia, and Spirochete are sensitive to this product. Enterococci are resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, Yersinia, etc. are also sensitive to this product. There is cross-resistance between this product and different varieties of tetracycline antibiotics. The mechanism of action of this product is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.

This product is a medium-acting sulfonamide. It has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Shigella and other Enterobacteriaceae, gonococci, meningococci, Haemophilus influenzae. In addition, it also has antimicrobial activity against Chlamydia trachomatis, Nocardia asteroides, Plasmodium and Toxoplasma in vitro. The antibacterial activity of this product is the same as that of sulfamethoxazole. However, in recent years, bacterial resistance to this product has increased, especially Streptococcus, Neisseria and Enterobacteriaceae. Sulfonamides are broad-spectrum antibacterial agents. This product is similar in structure to para-aminobenzoic acid (PABA), and can compete with PABA on dihydrofolate synthase in bacteria, thereby preventing PABA from being used as a raw material to synthesize folic acid required by bacteria, reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purine, thymidine and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria.

It competes with p-aminobenzoic acid for dihydrofolate synthase, blocking the synthesis of bacterial tetrahydrofolate; when used in combination with SMZ and TMP, it enhances the antibacterial effect and reduces drug-resistant strains.

It competes with p-aminobenzoic acid for dihydrofolate synthetase, blocking the synthesis of bacterial tetrahydrofolate; when used in combination with SD and TMP, it enhances the antibacterial effect and reduces drug-resistant strains.

By inhibiting bacterial dihydrofolate reductase, it prevents the reduction of dihydrofolate to tetrahydrofolate; when used in combination with SMZ and SD, it enhances the antibacterial effect and reduces drug-resistant strains.